

R H I N O M E D

TURBINE GRANTED US FDA REGISTRATION

- **Turbine™ successfully granted registration with US FDA as a medical device**
- **Important step in expanding marketing plans for the Turbine™**
- **Allows entry into the US, the world's largest healthcare and sports market**
- **The Turbine™ is an internal nasal dilator that increases airflow by an average of 38%**
- **Recent independent high performance product trial demonstrated two-thirds of riders increasing their power output at an average of 6.5% using the Turbine™.**

Melbourne, Australia – 17th July 2014:

Medical technology company Rhinomed Limited (ASX: RNO) is pleased to announce that its sport technology the Turbine™ has been successfully granted registration with the US Food and Drug Administration (FDA) as a medical device.

The Turbine™ is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a valuable to solution to dyspnea (breathlessness) during aerobic exercise.

A recent independent high performance product trial was carried out by former Olympic Cyclist, Rob Crowe at Ridewiser Studio in Melbourne, Australia and was announced on 13th May 2014. The results are exciting and compelling, with two-thirds of professional high performance riders increasing their power output at an average of 6.5%.

CEO Michael Johnson said “This is an important step in our plans to take the Rhinomed technology to the world's largest healthcare and sports markets. There are over 52 million members of health clubs in the USA and over 40 million cyclists. Successfully granting US FDA registration of the Turbine™ is an important step in allowing the Turbine™ to go this market with a premium positioning - as a FDA class 1 medical device in the US.”

The Turbine is currently sold on line and at selected retail outlets in Australia. Mr Johnson said. “Registration granted to the Turbine™ by the US FDA allows us to have a much wider range of discussions with US based retailers and wholesalers. It's a great achievement by the Rhinomed team and a clear next step for the company to expand in the US market.”

R H I N O M E D

Media Enquiries

Michael Johnson, CEO & Director

+61 (03) 8416 0900

mjohnson@rhinomed.com.au

Follow us on twitter at [@rhinomedceo](https://twitter.com/rhinomedceo) and [@theturbinecom](https://twitter.com/theturbinecom) and on www.facebook.com/theturbine

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its BreatheAssist technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.com.au.

About the Turbine™

The **Turbine™** is a revolutionary respiratory technology designed specifically for the sport market. The Turbine delivers an average increase of 38% more airflow through the nasal passages. The **Turbine™** product range has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training. You can purchase a turbine by visiting www.theturbine.com